Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the severity of atherosclerosis in coronary artery or in stent restenosis was not related to any polymorphism of stromelysin-1 or gelatinase B.
|
12205736 |
2002 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The serum levels of matrix metalloproteinase (MMP)-3 and -9 are significantly elevated in KD patients, and polymorphisms in the genes encoding MMP-3 and MMP-9 have been associated with the susceptibility, severity, and progression of atherosclerosis and aneurysm.
|
18810583 |
2008 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Current data provide evidence for the role of MMP3 polymorphism in plaque destabilisation, but elucidation of the role of other MMP gene variants in atherosclerosis will depend on better study design, including a larger sample size, extensive screening of individual genes with haplotype analysis and replication of studies to avoid publication bias.
|
16905683 |
2006 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies have demonstrated that matrix metalloproteinase-3 (MMP-3) is involved in the development and progression of atherosclerosis.
|
28843428 |
2017 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together with previous findings, these results primarily implicate MMP-3 in atherosclerosis progression rather than in acute MI.
|
16629857 |
2006 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men.
|
12485468 |
2002 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The stromelysin-1 genotype was determined for 496 men with coronary artery disease and cholesterol levels between 4.0 and 8.0 mmol/L, participating in the Regression Growth Evaluation Statin Study (REGRESS) study, a clinical trial assessing the effect of the lipid-lowering drug pravastatin on the progression of atherosclerosis.
|
10190398 |
1999 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The joint action of two susceptibility loci, rather than single MMP genes alone, and the particular combination of MMP3 and MMP9 genotypes present at these loci may contribute to heterogeneity in the presentation of atherosclerosis.
|
15823277 |
2005 |
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The functional genetic polymorphisms present in the promoters of stromelysin-1 (MMP3) and gelatinase B (MMP9) have been shown to be associated with angiographically measured atherosclerosis; however, haplotype analysis of the genetic polymorphisms occurring in the promoters and coding regions of MMP3 and MMP9 has been infrequently performed in the past.
|
19438845 |
2009 |
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Through screening expression patterns of typical genes involved in atherosclerosis and foam cell generation, we could demonstrate that mRNA levels of cyclooxygenase-2, interleukin 1beta, and tumor necrosis factor-alpha were increased in a time- and dose-dependent manner in U937 macrophages treated with TCDD, like oxLDL, and that these changes accompanied significantly elevated levels of matrix-degrading metalloproteinases (MMP)-1, MMP-3, MMP-12, and MMP-13.
|
15531779 |
2004 |
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis.
|
11116068 |
2000 |